Cipla share price falls over 2% after weak Q3FY26 results; profit drops 57% YoY, brokerages cut targets citing US headwinds.

Jan 23 (Reuters) - Cipla, India's third-largest drugmaker by revenue, reported a 57% quarterly profit decline on Friday as ...

Jan 23 (Reuters) - Cipla, India's third-largest drugmaker by revenue, reported a steeper-than-expected 57% fall in quarterly ...

Cipla shares traded lower after the drugmaker reported a sharp year-on-year decline in December-quarter profit, prompting ...

Motilal Oswal recommended Neutral rating on Cipla with a target price of Rs 1310 in its research report dated January 24, 2026.

Several brokerages downgraded Cipla following a weaker-than-expected December quarter performance, citing softness in US ...

Stay up-to-date with the Cipla Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...

India’s third-largest pharmaceutical company, Cipla, on Friday reported that its net profit dropped 57 per cent year on year ...

Cipla's Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the quarter stood at ₹1,255 crore compared to ₹1,989 crore last year, a 36.7% drop, and well below the CNBC-TV18 poll ...

In light of Cipla's weak Q3 earnings, brokerages including Goldman Sachs, HSBC, and BofA have all cut target price on the ...

Drugmakers Sun Pharma, Cipla, Zydus and Graviti Pharmaceuticals are recalling different products in the U.S., most of them over manufacturing issues.

The organisers of the Totalsports Two Oceans Marathon (TTOM) have announced Cipla as the official Recovery Partner, beginning ...